Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$93,435 | -$62,680 | -$55,278 | -$43,513 |
| Dep. & Amort. | $471 | $278 | $1,067 | $1,001 |
| Deferred Tax | $0 | $0 | $0 | -$2,422 |
| Stock-Based Comp. | $6,716 | $5,887 | $5,447 | $2,770 |
| Change in WC | -$6,346 | -$4,885 | $4,555 | $13,922 |
| Other Non-Cash | $22,583 | -$1,904 | $824 | $2,422 |
| Operating Cash Flow | -$70,011 | -$63,304 | -$43,385 | -$25,820 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,338 | -$1,047 | -$164 | -$3,385 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$47,949 | -$122,423 | -$64,842 | $0 |
| Inv. Sales/Matur. | $130,592 | $110,886 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $80,305 | -$12,584 | -$65,006 | -$3,385 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $8,818 | $69,242 | $100,495 | $604 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$287 | -$3,551 | -$4,238 | -$245 |
| Financing Cash Flow | $8,531 | $65,691 | $96,257 | $359 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $18,825 | -$10,197 | -$12,134 | -$28,846 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $23,745 | $33,942 | $46,076 | $74,922 |
| End Cash | $42,570 | $23,745 | $33,942 | $46,076 |
| Free Cash Flow | -$72,349 | -$64,351 | -$43,549 | -$29,205 |